GlassScriptPhysician profile
Alan Saven
NPI 1184680399
$323,004.14
in general payments reported to CMS, 2019-2025
51 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74K · 2020: $88K · 2021: $45K · 2022: $49K · 2023: $37K · 2024: $17K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $60K · Consulting Fee: $4,215 · Food and Beverage: $3,621 · Travel and Lodging: $141 · Education: $32.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $59,822.50 |
| Consulting Fee | $4,215.00 |
| Food and Beverage | $3,620.56 |
| Travel and Lodging | $141.20 |
| Education | $32.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $48,260.63 | 2019-2023 | Jakafi |
| Karyopharm Therapeutics INC. | $28,336.12 | 2020-2023 | Xpovio |
| Astrazeneca Pharmaceuticals LP | $27,504.89 | 2019-2024 | Imfinzi |
| Beigene USA, INC. | $26,658.08 | 2020-2024 | Brukinsa |
| Celgene Corporation | $26,655.51 | 2019-2025 | Pomalyst, Breyanzi, Reblozyl |
| Abbvie INC. | $25,711.91 | 2019-2025 | Venclexta |
| Janssen Biotech, INC. | $25,592.62 | 2019-2023 | Imbruvica |
| Dova Pharmaceuticals | $21,387.95 | 2019-2021 | |
| Glaxosmithkline, LLC. | $19,205.77 | 2020-2024 | Ojjaara, Jemperli |
| Beone Medicines USA, INC. | $13,138.09 | 2025 | Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $13,131.63 | 2019-2023 | Imbruvica |
| Takeda Pharmaceuticals U.S.A., INC. | $9,596.63 | 2019-2020 | |
| Sobi, INC | $9,050.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $8,516.07 | 2019-2023 | Opdualag, Pomalyst |
| Seagen INC. | $4,395.95 | 2019-2020 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Saven listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.